ClinicalTrials.gg
Active, not recruitingNCT07531862ALIGNUpdated Jun 4, 2026

Spina Bifida Healthcare Navigator Program

An interventional study of Behavioral Treatment in Spina Bifida, sponsored by University of Pittsburgh. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Many adults with spina bifida experience difficulties managing their health-such as coordinating care across multiple providers, keeping up with medications, and navigating insurance systems. These tasks require strong thinking skills like planning, organizing, and problem-solving, which are often called "executive functions." Many adults with spina bifida have challenges with these skills due to differences in brain development associated with the condition. When a person's thinking abilities do not match the demands placed on them by their healthcare and daily routines, health problems often follow. Despite this, very few programs exist to help adults with spina bifida address this gap.

This study tests a new program called ALIGN (Navigating Life with Spina Bifida), developed at the UPMC Adult Spina Bifida Clinic. ALIGN was co-designed with a healthcare provider who is also an adult living with spina bifida. The program helps participants improve the fit between their abilities and their environment through two approaches: building personal skills and strategies, and arranging supports and routines to make demands more manageable. ALIGN includes six virtual group sessions and one individual session with a clinician.

Participants will be adults (age 18 or older) with spina bifida. They will complete questionnaires before and after the program measuring confidence in managing health, mood, and ability to participate in daily activities. A separate group of participants who do not take part in ALIGN will complete the same questionnaires for comparison. The main goals are to determine whether ALIGN is practical to deliver, acceptable to participants, and associated with early signs of benefit.

02

Conditions studied

  • Spina Bifida

Keywords

  • spina bifida
  • executive functioning
  • neuropsychology
  • rehabilitation psychology
  • health behavior
  • psychotherapy
  • cognitive-behavioral therapy
  • myelomeningocele
  • self-management
03

In context

Spinal Dysraphism

142 studies on the registry are indexed under Spinal Dysraphism; 39 are open to participants now.

This study's planned enrollment of 24 is below the median of 30 across 91 interventional studies indexed under Spinal Dysraphism.

Browse Spinal Dysraphism studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (18 years or older) diagnosed with spina bifida (SB), including any type (e.g., myelomeningocele, meningocele, lipomyelomeningocele).
  • Individuals who are able to participate in educational and interactive sessions (in-person at UPMC Mercy or remotely via secure teleconferencing).
  • English fluency

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age
  • Non-English fluency
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants in this arm will engage in the experimental intervention (ALIGN), which is a six-session, group-based cognitive-behavioral therapy program that is followed by a seventh, individual coaching session with a study clinician. Relevant data will be collected pre-/post-intervention

    Behavioral: Behavioral Treatment

  • No intervention
    Control

    Participants in this arm will participate in a waitlist control condition. Data will collected at a time interval that approximates the intervention arm.

Interventions

  • BehavioralBehavioral Treatment

    The intervention being tested in this study (ALIGN) is designed to improve the fit between an individual's abilities and their environment. This is accomplished through two complementary approaches: building personal skills and strategies ("build"), and arranging supports and routines to make demands more manageable ("scaffold"). ALIGN includes six virtual group sessions and one individual session with a clinician. The intervention fits within the broad umbrella of "third-wave" cognitive-behavioral therapies. It emphasizes psychological flexibility as an important treatment component.

    Also known as: Spina Bifida Healthcare Navigator Program

06

What researchers measure

Primary outcomes

  1. Acceptability of Intervention Measure (AIM)

    This measure assesses perceived acceptability of an intervention. The scale consists of 4 items, each rated on a 5-point Likert scale (1 = completely disagree to 5 = completely agree). Scores are calculated as the mean of all items, yielding a score range of 1 to 5. Higher scores indicate greater perceived acceptability. No items are reverse scored.

    Time frame: post-intervention (approximately two months after enrollment; administered only to participants assigned to the intervention group)

  2. Intervention Appropriateness Measure (IAM)

    This measure assesses perceived appropriateness of an intervention, defined as its perceived fit, relevance, or compatibility for a given context or population. The scale consists of 4 items, each rated on a 5-point Likert scale (1 = completely disagree to 5 = completely agree). Scores are calculated as the mean of all items, yielding a score range of 1 to 5. Higher scores indicate greater perceived appropriateness. No items are reverse scored.

    Time frame: post-intervention (approximately two months after enrollment; administered only to participants assigned to the intervention group)

  3. Feasibility of Intervention Measure (FIM)

    This measure assesses perceived feasibility of implementing an intervention within a given setting. The scale consists of 4 items, each rated on a 5-point Likert scale (1 = completely disagree to 5 = completely agree). Scores are calculated as the mean of all items, yielding a score range of 1 to 5. Higher scores indicate greater perceived feasibility. No items are reverse scored.

    Time frame: post-intervention (approximately two months after enrollment; administered only to participants assigned to the intervention group)

Secondary outcomes

  1. Change in PROMIS Depression Measure

    This measure assesses severity of depressive symptoms, including affective and cognitive components of depression. Scores are reported as T-scores standardized to the U.S. general population (mean = 50, standard deviation = 10). Higher T-scores indicate greater depressive symptom severity. Scores are generated using PROMIS computer adaptive testing algorithms; raw item scores are not summed.

    Time frame: Enrollment to approximately two months

  2. Change in Partners in Health (PIH) Scale

    The PIH Scale assesses self-management capacity in individuals with chronic health conditions, including knowledge, treatment adherence, symptom monitoring, and management of physical, emotional, and social impacts. The scale includes 12 items, each rated from 0 to 8, producing a total score range of 0-96. Higher scores indicate greater self-management capacity. Item scores are summed to compute the total score; subscale scores (e.g., condition and treatment knowledge, coping, condition management, treatment adherence) may also be examined descriptively but are not required for total score computation.

    Time frame: Enrollment to approximately two months

  3. Change in Acceptance and Action Questionnaire-2 (AAQ-2)

    The AAQ-2 measures psychological inflexibility and experiential avoidance, core constructs within Acceptance and Commitment Therapy. The scale contains 7 items, each rated on a 7-point Likert scale (1-7), yielding a total score range of 7-49. Higher total scores indicate greater psychological inflexibility and experiential avoidance, whereas lower scores indicate greater psychological flexibility. Items are summed after required reverse scoring to produce the total score.

    Time frame: Enrollment to approximately two months

  4. Change in PROMIS Self-Efficacy (Managing Daily Activities)

    This measure assesses perceived confidence in performing various activities of daily living related to chronic health conditions, such as routine tasks, exercise, and managing activities in challenging situations. Scores are reported as T-scores standardized to a calibration population (mean = 50, standard deviation = 10). Higher T-scores indicate greater self-efficacy in managing daily activities. Scores are generated using PROMIS computer adaptive testing algorithms based on item response theory; raw item scores are not summed.

    Time frame: Enrollment to approximately two months

  5. Change in PROMIS Participation Measure

    This measure assesses perceived ability to participate in social roles and activities, including work, family, and community functioning. Scores are reported as T-scores standardized to the U.S. general population (mean = 50, standard deviation = 10). Higher T-scores indicate greater ability to participate in social roles and activities. Scores are generated using PROMIS computer adaptive testing algorithms based on item response theory; raw item scores are not summed.

    Time frame: Enrollment to approximately two months

  6. Change in PROMIS Anxiety Measure

    This measure assesses severity of anxiety symptoms, including fear, worry, and physiological arousal. Scores are reported as T-scores standardized to the U.S. general population (mean = 50, standard deviation = 10). Higher T-scores indicate greater anxiety symptom severity. Scores are generated using PROMIS computer adaptive testing algorithms; raw item scores are not summed.

    Time frame: Enrollment to approximately two months

  7. Change in PROMIS Self-Efficacy (Managing Symptoms)

    This measure assesses perceived confidence in the ability to manage and control symptoms associated with chronic health conditions across a variety of settings and situations. Scores are reported as T-scores standardized to a calibration population (mean = 50, standard deviation = 10). Higher T-scores indicate greater self-efficacy in managing symptoms. Scores are generated using PROMIS computer adaptive testing algorithms based on item response theory; raw item scores are not summed.

    Time frame: Enrollment to approximately two months

  8. Change in PROMIS Self-Efficacy (Managing Medications and Treatments)

    This measure assesses perceived confidence in managing medication regimens and treatment-related tasks associated with chronic health conditions, including adherence, scheduling, and navigating treatment decisions. Scores are reported as T-scores standardized to a calibration population (mean = 50, standard deviation = 10). Higher T-scores indicate greater self-efficacy in managing medications and treatments. Scores are generated using PROMIS computer adaptive testing algorithms based on item response theory; raw item scores are not summed.

    Time frame: Enrollment to approximately two months

  9. Change in PROMIS Self-Efficacy (Managing Emotions)

    This measure assesses perceived confidence in managing emotional responses related to living with chronic health conditions, including worry, frustration, and discouragement. Scores are reported as T-scores standardized to a calibration population (mean = 50, standard deviation = 10). Higher T-scores indicate greater self-efficacy in managing emotions. Scores are generated using PROMIS computer adaptive testing algorithms based on item response theory; raw item scores are not summed.

    Time frame: Enrollment to approximately two months

  10. Change in PROMIS Self-Efficacy (Managing Social Interactions)

    This measure assesses perceived confidence in managing social situations and interpersonal interactions related to living with chronic health conditions, including communicating needs and participating in social activities. Scores are reported as T-scores standardized to a calibration population (mean = 50, standard deviation = 10). Higher T-scores indicate greater self-efficacy in managing social interactions. Scores are generated using PROMIS computer adaptive testing algorithms based on item response theory; raw item scores are not summed.

    Time frame: Enrollment to approximately two months

Other outcomes

  1. Change in Grit-12

    The Grit-12 measures perseverance of effort and consistency of interests toward long-term goals. It contains 12 items rated on a 5-point Likert scale, producing a total score range of 1-5 when averaged. Higher scores indicate greater grit. Items are averaged after appropriate reverse scoring to compute the total score; subscale scores for perseverance and consistency may also be derived.

    Time frame: Enrollment to approximately two months

  2. Change in Interpersonal Support Evaluation List-12 (ISEL-12)

    The ISEL-12 assesses perceived availability of social support, including appraisal, belonging, and tangible support. The scale includes 12 items rated on a 4-point Likert scale, yielding a total score range of 12-48. Higher scores indicate greater perceived social support. Item scores are summed to produce the total score; subscale scores (e.g., appraisal, belonging, tangible support) can also be computed.

    Time frame: Enrollment to approximately two months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No. This study is a small, pilot, underpowered feasibility project designed to assess acceptability, feasibility, and preliminary signals rather than to support confirmatory hypothesis testing. The sample size and study design limit the reliability and generalizability of individual participant data for secondary analyses, and no formal data-sharing infrastructure or governance plan was established for this pilot. Aggregate results may be disseminated through scholarly publication, but individual participant-level data will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2026, 4 months after the start.

Of 60 non-industry interventional studies with no phase under Spinal Dysraphism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 4 months is below that.

Counting every sponsor, half of 62 studies reached it within 31 months; a quarter within 20 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 15, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Aug 2026
CompletionEst.
Sep 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07531862
Collaborators
Fisa Foundation
Responsible party
Ted Allaire Barrios (Assistant Professor, University of Pittsburgh) — Principal investigator
First posted
Apr 15, 2026
Start date
Apr 15, 2026
Primary completion
Aug 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jun 4, 2026

Study contacts

Ted A Barrios, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion